A partnership agreement that Saiba Animal Health concluded in October 2019 is now bearing additional fruit: An unnamed partner has exercised its option for an exclusive license for the commercialization and development of one of Saiba’s product candidates, further details of which can be found in a press release. The license agreement has also triggered a “significant upfront payment”, Saiba writes. The veterinary company based in Freienbach in the Greater Zurich Area will use this to further develop its technology and advance other pipeline candidates.
“This significant step in our collaboration was the result of a compelling preclinical data-set generated by the R&D teams of both parties over the course of the initial research agreement”, comments Dr. Gary T. Jennings, CEO of Saiba Animal Health, in the press release. “We view our partner's commitment as recognition of the potential of our platform technology to be translated into cost-effective therapies for companion animals”, he adds. On its website, Saiba names the British biotechnology firm Benchmark Holdings PLC as a development partner.
Saiba Animal Health was founded in 2013 as a spin-off from the University of Zurich It was awarded the Swiss Technology Award for its concept of neutralizing the major cat allergen that causes allergies and asthma in humans by simply vaccinating cats with the HypoCat vaccine developed by Saiba. mm
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space